SHUKRAPHAR54.00

Shukra Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSUNLOC
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
Non-current Assets
+ Property, Plant & Equipment20.219.9
+ Capital Work-in-Progress1.7
Current Assets
+ Inventories3.22.3
+ Trade Receivables30.224.5
+ Cash & Cash Equivalents4.010.0
+ Other Bank Balances10.0
+ Short-term Loans2.32.0
+ Other Current Assets13.217.1
Total Assets75.077.8
Equity
+ Equity Share Capital3.910.9
+ Other Equity / Reserves21.446.7
Total Equity25.357.6
Liabilities
+ Borrowings — Non-current3.8
+ Deferred Tax Liabilities3.33.3
+ Other Non-current Liabilities0.1
+ Borrowings — Current1.32.7
+ Trade Payables34.37.2
+ Other Current Liabilities6.95.6
Total Equity & Liabilities75.077.8
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.